Associação entre a exposição a desreguladores endócrinos e desenvolvimento de doença hepática gordurosa não alcóolica / Association between exposure to endocrine deregulators and development of non alcoholic fat hepatic disease

Letícia Felipe Félix, Elaine Barros Ferreira, Priscilla Roberta Silva Rocha

Abstract


Estudos têm revelado a relação entre a exposição a compostos ambientais e o desenvolvimento de danos hepáticos. Objetivo: identificar evidências de associação entre a exposição humana aos desreguladores endócrinos e a ocorrência de desenvolvimento de doença hepática gordurosa não alcoólica. Método: revisão integrativa de literatura, as buscas foram realizadas nas bases de dados eletrônicas Cochrane, PubMed, LILACS, e Science Direct. Foram incluídos estudos primários em humanos, que abordaram o desfecho de interesse, sem restrição temporal, publicados em inglês, português ou espanhol. Resultados: de 209 artigos identificados, 12 foram selecionados, todos em língua inglesa, sendo 50% estudos transversais, 33% de coorte e 16% de casos-controle. A mensuração da exposição aos desreguladores endócrinos ocorreu por meio da análise de amostras de urina, sangue ou solo. A exposição ao Bisfenol A e Trialometanos foi associada à ocorrência de acúmulo de gordura hepática, especialmente em indivíduos obesos, do sexo masculino e de origem hispânica. Conclusão: os achados desta revisão evidenciam a associação entre exposição a desreguladores endócrinos  e a ocorrência de danos hepáticos,  indicando a necessidade do desenvolvimento de estratégias para evitar a exposição sobretudo em pacientes de maior risco.

 

 


Keywords


“Disruptores Endócrinos”, “Exposição Ambiental”, “Fígado Gorduroso”.

References


El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol. 2008 Jul;14(26):4120-6. DOI: 10.3748/wjg.14.4120

Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3): 167–175. PMC4836586

Foulds CE, Treviño LS, York B, Walker CL. Endocrine-disrupting chemicals and fatty liver disease. Nat Rev Endocrinol. 2017 Aug;13(8):445-457. DOI: 10.1038/nrendo.2017.42.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. DOI: 10.1002/hep.25762.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. DOI: 10.1002/hep.28431.

Guyton AC. Digestão e assimilação de carboidratos, gorduras e proteínas. In: Guyton AC. Fisiologia Humana. 6 ed. Rio de Janeiro: Guanabara Koogan;1988, 413-428.

Treviño LS, Katz TA. Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease. Endocrinology. 2018 Jan 1;159(1):20-31. DOI: 10.1210/en.2017-00887.

Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009 Jun;30(4):293-342. DOI: 10.1210/er.2009-0002.

Endocrine Society. Introduction to endocrine disrupting chemicals (EDCS). A guide for public interest organizations and policy-makers. An Endocrine society – Hormone Science to health, 2014. Disponível em: https://www.endocrine.org/topics/edc/introduction-to-edcs

Al-Eryani L, Wahlang B, Falkner KC, Guardiola JJ, Clair HB, Prough RA, Cave M. Identification of Environmental Chemicals Associated with the Development of Toxicant-associated Fatty Liver Disease in Rodents. Toxicol Pathol. 2015 Jun; 43(4):482-497. DOI: 10.1177/0192623314549960.

Das S, Seth RK, Kumar A, Kadiiska MB, Michelotti G, Diehl AM, Chatterjee S. Purinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(12):950-963. DOI: 10.1152/ajpgi.00235.2013.

Rönn M, Kullberg J, Karlsson H, Berglund J, Malmberg F, Orberg J, Lind L, Ahlström H, Lind PM. Bisphenol A exposure increases liver fat in juvenile fructose-fed Fischer 344 rats. Toxicology. 2013 Jan; 303:125-32. DOI: 10.1016/j.tox.2012.09.013.

Shan Q, Huang F, Wang J, Du Y. Effects of co-exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polychlorinated biphenyls on nonalcoholic fatty liver disease in mice. Environ Toxicol. 2015 Dec;30(12):1364-74. DOI: 10.1002/tox.22006.

Melnyk BM, Fineout-Overholt E. Evidence based pratice in nursing and healthcare. 3 ed. Philadelphia: Wolters Kluwer/ Lippincott Williams & Wlkins, 2014, 35-37.

Soares CB, Hoga LAK, Peduzzi M, Sangaleti C, Yonekura T, Silva DRAD. Revisão integrativa: conceitos e métodos utilizados na enfermagem. Rev Esc Enferm USP. 2014; 48(2):335-45. DOI: 10.1590/S0080-623420140000200020.

Khalil N, Ebert JR, Wang L, Belcher S, Lee M, Czerwinski SA, Kannan K. Bisphenol A and cardiometabolic risk factors in obese children. Sci Total Environ. 2014 Feb 1;470-471:726-32. DOI: 10.1016/j.scitotenv.2013.09.088. [incluído na revisão]

Verstraete SG, Wojcicki JM, Perito ER, Rosenthal P. Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003–2010. Environ Health. 2018 Feb 1;17(1):12. DOI: 10.1186/s12940-018-0356-3. [incluído na revisão]

Cotrim HP1, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver. 1999 Aug;19(4):299-304. [incluído na revisão]

Frediani JK, Naioti EA, Vos MB, Figueroa J, Marsit CJ, Welsh JA. Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014. Environ Health. 2018 Jan 15;17(1):6. DOI: 10.1186/s12940-017-0350-1. [incluído na revisão]

Makris KC, Andrianou XD, Charisiadis P, Burch JB, Seth RK, Ioannou A, Picolos M, Christophi CA, Chatterjee S. Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus. Environ Int. 2016 Jul-Aug;92-93:486-493. DOI: 10.1016/j.envint.2016.04.012. [incluído na revisão]

Hyder O, Chung M, Cosgrove D, Herman JM, Li Z, Firoozmand A, Gurakar A, Koteish A, Pawlik TM. Cadmium Exposure and Liver Disease among US Adults. J Gastrointest Surg. 2013 Jul;17(7):1265-73. DOI: 10.1007/s11605-013-2210-9. [incluído na revisão]

Deguti MM, Sipahi AM, Gayotto LCC, Palácios SA, Bittencourt PL, Goldberg AC, Laudanna AA, Carrilho FJ, Cançado ELR. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. Braz J Med Biol Res. 2003 Jun; 36(6): 739-745. DOI:10.1590/S0100-879X2003000600009. [incluído na revisão]

Yang J, Wei Q, Peng X, Peng X, Yuan J, Hu D. Relationship between Methyl Tertiary Butyl Ether Exposure and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Petrol Station Attendants in Southern China. Int J Environ Res Public Health. 2016 Sep 23;13(10):946-954. DOI: 10.3390/ijerph13100946. [incluído na revisão]

Burch JB, Everson TM, Seth RK, Wirth MD, Chatterjee S. Trihalomethane exposure and biomonitoring for the liver injury indicator, alanine aminotransferase, in the United States population (NHANES 1999-2006). Sci Total Environ. 2015 Jul 15;521-522:226-34. DOI: 10.1016/j.scitotenv.2015.03.050. [incluído na revisão]

Cave M, Appana S, Patel M, Falkner KC, McClain CJ, Brock G. Polychlorinated biphenyls, lead, and mercury are associated with liver disease in American adults: NHANES 2003-2004. Environ Health Perspect. 2010 Dec;118(12):1735-42. DOI: 10.1289/ehp.1002720. [incluído na revisão]

Dallio M, Masarone M, Errico S, Gravina AG, Nicolucci C, Di Sarno R, Gionti L, Tuccillo C, Persico M, Stiuso P, Diano N, Loguercio C, Federico A. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Aliment Pharmacol Ther. 2018 Mar;47(6):826-837. DOI: 10.1111/apt.14499. [incluído na revisão]

Lin Y-C, Lian I-B, Kor C-T, Chang C-C, Su P-Y, Chang W-T, Liang Y-F, Su W-W, Soon M-S. Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. BMJ Open 2017;7:e014215. DOI:10.1136/bmjopen-2016-014215. [incluído na revisão]

Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007 Dec 21;13(47):6419-24. DOI:10.3748/wjg.v13.i47.6419

Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007 Aug;46(2):582-9. DOI:10.1002/hep.21768

SOCIEDADE BRASILEIRA DE HEPATOLOGIA. Doença Gordurosa Não Alcoólica Do Fígado: Reunião Monotématica da SBH. Mai 2012. Disponível em: http://www.sbhepatologia.org.br/pdf/reuniao_monotematica_dhgna_2012.pdf

Karnikowski M, Córdova C, Oliveira RJe, Karnikowski MGO, Nóbrega OT. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and older adults. Sao Paulo Med. J. 2007 Nov ; 125(6): 333-337. DOI: 10.1590/S1516-31802007000600006.

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015 Apr;62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012.

Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013 Feb;98(2):483-95. DOI: 10.1210/jc.2012-3093.

Silva GH, Escanhoela CAF. Doença hepática gordurosa não alcoólica: patogênese e achados histológicos com ênfase nas alterações mitocondriais. Rev. Ciênc. Méd, Campinas. 2009; 18 (5/6): 269-279.

Huang JC, Lin HY, Lim LM, Chen SC, Chang JM, Hwang SJ, Tsai JC, Hung CC, Chen HC. Body mass index, mortality, and gender difference in advanced chronic kidney disease. PLoS One. 2015 May 5;10(5): e0126668. DOI: 10.1371/journal.pone.0126668

Cheng HY, Wang HY, Chang WH, Lin SC, Chu CH, Wang TE, Liu CC, Shih SC. Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with Metabolic Syndrome and Insulin Resistance. Int J Gerontol. 2013; 3 (4): 194-198. DOI: 10.1016/j.ijge.2013.03.008

WORLD GASTROENTEROLOGY ORGANISATION GLOBAL GUIDELINE. Doença hepática gordurosa não alcoólica e esteatohepatite não alcoólica. Jun 2012. Disponível em: http://www.worldgastroenterology.org/guidelines/global-guidelines/nafld-nash/nafld-nash-portuguese

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004 Dec;40(6):1387-95. DOI: 10.1002/hep.20466

Menale C, Piccolo MT, Cirillo G, Calogero RA, Papparella A, Mita L, Del Giudice EM, Diano N, Crispi S, Mita DG. Bisphenol A effects on gene expression in adipocytes from children: association with metabolic disorders. J Mol Endocrinol. 2015 Jun;54(3):289-303. DOI: 10.1530/JME-14-0282.

Lee S, Lee HA, Park B, Han H, Park BH, Oh SY, Hong YS, Ha EH, Park H. A prospective cohort study of the association between bisphenol A exposure and the serum levels of liver enzymes in children. Environ Res. 2018 Feb;161:195-201. DOI: 10.1016/j.envres.2017.11.007.

Fontenele EGP, Martins MRA, Quidute ARP, Júnior Montenegro RM. Environmental contaminants and endocrine disruptors. Arq Bras Endocrinol Metab. 2010; 54(1): 6-16. DOI: 10.1590/S0004-27302010000100003

Polyzos SA, Kountouras J, Deretzi G, Zavos C, Mantzoros CS. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med. 2012 Jan;12(1):68-82. DOI: 10.2174/156652412798376161

Bertoli S, Leone A, Battezzati A. Human Bisphenol A Exposure and the "Diabesity Phenotype". Dose Response. 2015 Jul 31;13(3):1559325815599173. DOI: 10.1177/1559325815599173.

Das S, Kumar A, Seth RK, Tokar EJ, Kadiiska MB, Waalkes MP, Mason RP, Chatterjee S. Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity. Toxicol Appl Pharmacol. 2013 Jun 15;269(3):297-306. DOI: 10.1016/j.taap.2013.02.003.

Seth RK, Kumar A, Das S, Kadiiska MB, Michelotti G, Diehl AM, Chatterjee S. Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice. Toxicol Sci. 2013 Aug;134(2):291-303. DOI: 10.1093/toxsci/kft104.




DOI: https://doi.org/10.34117/bjdv6n3-260

Refbacks

  • There are currently no refbacks.